Page 16 - Glenmark Pharmaceuticals

Glenmark Pharma gets final USFDA nod for menopause symptom relief drug

The approved product is a generic version of Novo Nordisk Inc's VAGIFEM

Glenmark to boost cash flows, pare debt as it eyes a lighter balance sheet

Pharma major is monetising assets through licensing arrangements, restructuring operations

Glenmark in deal with Chinese firm Harbour BioMed for innovative molecule

With a stringent regulatory environment in China, not many Indian companies have been able to conduct clinical trials in that market

Glenmark Pharmaceuticals to file appeal before NCLAT against CCI penalties

Drug firm Glenmark Pharmaceuticals today said it will file an appeal against the order of the Competition Commission of India (CCI) before the National Company Law Appellate Tribunal. On July 13, CCI had imposed penalties totalling nearly Rs 47 crore on Glenmark Pharmaceuticals, its three officials, two other pharma companies and four Gujarat-based chemists associations for indulging in unfair business practices. Besides, a carry and forward (C&F) agent had also been penalised. M/s Reliance Medical Agency had filed a complaint with the CCI against the Chemist & Druggist Association of Baroda including pharma companies and C&F agents alleging that prior to being appointed as stockist they were required to obtain NOC from the local Chemist and Druggist Associations in Gujarat, Glenmark said in a BSE filing. "The Commission has relied on findings of the Director General and held that Glenmark is mandating no-objection certificates (NOC) from the trade associations for ...

Glenmark launches drug for chemotherapy-induced nausea in India, Nepal

The product has been developed by Swiss pharma group, Helsinn and Glenmark has exclusive marketing rights for it in India and Nepal

Glenmark's US facility to go onstream with nod for anti-malaria drug

Market size of drug is $40 mn. Having a manufacturing footprint in the US is part of company's game plan to mitigate regulatory risk

Glenmark Pharma hits 52-week low on subdued Q4 results

The stock hit a fresh 52-week low of Rs 484, slipped 9% on the BSE in early morning trade, after the company reported 17% decline in its consolidated net profit at Rs 1.52 billion in March quarter.

Glenmark recalls 100,000 bottles of drug over incorrect instrictions

The ongoing nationwide voluntary recall is a class III recall

Glenmark Pharma declines 9% on weak Q3 results

The stock fell 9% to Rs 524, its 52-week low on BSE trade after the company reported 78% fall in its consolidated net profit at Rs 1.05 billion for the quarter ended December 2017.

Expecting India, US, Europe to contribute over 80% sales by 2021: Glenmark

The company is also planning to scale up its speciality business in the US as part of its future outlook for 2021

Glenmark Pharma gets approval for inhaler product in Nordic countries

Glenmark Pharmaceuticals Europe Ltd today said it has received approval for an inhaled respiratory product in Nordic countries, including Sweden, Denmark, Norway, Finland and Iceland. The company "has successfully closed the decentralised registration procedure for generic Seretide Accuhaler in the Nordic region", Glenmark Pharma said in BSE filing. "This will be Glenmark's first inhaled respiratory product approval in Europe, and re-enforces Glenmark's commitment in the respiratory area," it said. The company added that the commercialisation of the product would depend on national approval as well as substitution and pricing approvals. Glenmark had entered into a strategic development and licensing agreement with Celon Pharma S.A. to develop and market a generic version of GlaxoSmithKline's Seretide Accuhaler product - Fluticasone / Salmeterol dry powder Inhaler in Europe. Glenmark Pharmaceuticals Chairman & MD Glenn Saldanha said: "We will continue to work in the .

Glenmark Pharma falls 3% as Baddi unit gets 7 observations from USFDA

The stock dipped 3% to Rs 574 on the BSE in intra-day trade.

Glenmark Pharma gets 7 US FDA observations for Baddi unit, to reply soon

Glenmark said its Baddi unit contributes approximately 10 per cent of the revenue of the US sales

Glenmark Pharma launches nicotine substitute gum Kwitz

Kwitz nicotine gum will be available in two variants of 2 mg as an OTC product 4mg as prescription product, the company said in a statement

Glenmark's Glenn Saldanha appointed IPA President

Indian Pharmaceutical Alliance (IPA), a body of major domestic pharma firms, today said Glenn Saldanha has been appointed as President for 2017-19. Saldanha is Chairman & Managing Director of Glenmark Pharmaceuticals. IPA also appointed Panacea Biotec Joint Managing Director Rajesh Jain as Vice President. The IPA, initially formed by eight national companies in November 1999, has now 20 research-based national pharmaceutical companies in its fold. Some of the prominent members include Lupin, Cadila Healthcare, Cipla, Dr Reddy's Laboratories and Sun Pharmaceutical Industries among others.

Risk-reward favourable for Glenmark

Growth momentum to continue in FY18 as firm beats peers in Q1, out-licensing deal a trigger

Glenmark Pharma records 47% jump in Q1 net at Rs 333 cr

The company continues to be one of the fastest growing companies in the pharma market

Glenmark Pharma's generic anti-inflammatory drug gets USFDA nod

Approval is for Indomethacin extended-release capsules of 75 mg strength, the company said

Glenmark gets USFDA's approval to sell generic blood pressure medicine

Glenmark's tablets will be manufactured by company's manufacturing facility located in Goa

Glenmark Pharma hits 52-week low post Q4 results

The stock hit 52-week low of Rs 716, down 5.5%, extending its Friday's 16% on BSE.